August 2026 Research Update

This month, studies looking at treatment outcomes in PNH added a clearer picture that lab control of hemolysis is only part of how people feel day to day. In routine care, quality of life tracked more strongly with anemia and fatigue than with a single lab definition of residual intravascular hemolysis. Separately, a cross-trial indirect comparison reported better blood-related outcomes with pegcetacoplan than crovalimab, though this kind of comparison cannot fully replace a head-to-head trial. [1] [2]

In a 97-person observational snapshot of adults already using complement inhibitors, people with hemoglobin under 10 g/dL reported worse overall health and functioning across multiple questionnaire areas. Residual intravascular hemolysis (defined by LDH) did not separate quality-of-life scores in the same way, and fatigue remained a major factor even when hemoglobin was taken into account. In plain terms, this highlights that tiredness and low blood counts can remain central problems even when a complement blocker is being used. [1]

A multinational survey also pointed to a gap between what patients experience and what clinicians perceive, with patients reporting more frequent and more severe symptoms for most common issues. Fatigue was especially prominent for patients, and patients were less satisfied with treatment than physicians reported being. Both groups most often preferred oral administration, though preferences still differed between patients and physicians. [3]

An indirect treatment comparison across clinical trials reported that pegcetacoplan performed better than crovalimab on measures such as transfusion avoidance, hemoglobin stabilization, and control of hemolysis in both C5-inhibitor-naive and C5-inhibitor-experienced groups. This kind of analysis compares results across separate studies rather than within one shared trial, so it is best read as a structured estimate rather than a definitive ranking. Even so, it adds to ongoing research interest in how different complement-targeting approaches may differ in real-world outcomes that matter to patients. [2]

For patients and caregivers, this month most clearly reinforces that anemia and fatigue are tightly linked to quality of life, even in people already treated with complement inhibitors. The observational and survey findings may matter now for understanding why someone can still feel unwell despite treatment, but they do not prove one strategy will fix fatigue for a specific person. The pegcetacoplan versus crovalimab comparison may matter later if supported by more direct comparisons, since it suggests differences in transfusions and hemoglobin stability, but it is not the same as a single head-to-head study. What remains uncertain is how much of fatigue relates to anemia versus other causes in PNH, and how best to measure patient experience in ways that match what people report in daily life. [1] [3] [2]

Studies focused on diagnosis and disease biology this month emphasized that PNH can unfold over time in ways that are easy to miss, and that the underlying PNH cell population can change in different directions. A Japanese claims-based cohort found that symptoms often appeared long before a definitive diagnosis, and longer delays were linked with more complications in descriptive analyses. A separate follow-up study tracking GPI-deficient blood cells reported that clone size can persist, expand, or regress, and that these patterns did not appear to depend on eculizumab. [4] [5]

In the Japanese database study of 160 people with definitively diagnosed PNH, over half had PNH-related symptoms recorded before the first diagnosis, and the median time from symptom onset to diagnosis was 26.5 months. The study also reported that complication rates (including kidney failure and thrombosis) increased with longer time from symptom onset to diagnosis, though claims data cannot capture every clinical detail behind those events. In plain language, this highlights how delays in recognition may coincide with more health problems over time, even if the study cannot prove the delay caused them. [4]

In a single-center retrospective follow-up of people with PNH or PNH with aplastic anemia overlap, the size of the PNH clone in neutrophils often moved in one of three directions: staying similar, expanding, or shrinking. Neutrophil clone size tracked closely with monocytes but not with lymphocytes, and larger expansions often involved multiple blood cell lineages. The study reported that these clone changes were largely independent of eculizumab, while some shrinkage was seen in people treated with anti-thymocyte globulin plus cyclosporine A, and complete eradication was observed after allogeneic stem cell transplantation in six patients. [5]

For patients, these studies add context for two common questions: why diagnosis can take time, and why PNH lab findings can change over the years. The diagnostic-delay findings may matter now mainly as an explanation of typical real-world timelines and the kinds of complications researchers track, but the study does not show what would happen for any one person with faster diagnosis. The clone-tracking study may matter over time because it shows that PNH clone size is not fixed and may not automatically shrink just because hemolysis is treated with eculizumab; it also shows that some settings (like after stem cell transplantation) can eliminate the clone in reported cases. What remains uncertain is how to best use changing clone size to predict symptoms or complications for an individual, since these reports were observational and from specific healthcare settings. [4] [5]

This month also included early and non-clinical work that does not tell us how patients will do, but helps explain where the field is trying to go. Laboratory research engineered a new C5-blocking fusion protein that fully blocked C5 under strong activation conditions in blood-cell lysis tests. Separate modeling work used pooled public data to estimate the eculizumab concentration linked to complete C5 inhibition and explored synthetic data to tighten the estimate, while another report discussed complement activation markers and testing consistency in Japan. A policy editorial emphasized that many people worldwide still cannot access complement inhibitors at all. [6] [7] [8] [9]

In lab experiments, a bifunctional fusion protein (RaCI-gly-OmCI) combined two tick-derived C5 inhibitors and showed very strong binding to C5. It achieved complete C5 inhibition in an alternative-pathway hemolysis test under strong complement activation, where the individual building blocks did not fully block C5 in that setting. This positions the fusion protein mainly as a research tool for studying how to stop terminal complement activity more completely, not as a tested patient treatment. [6]

A separate exploratory analysis pooled 390 paired measurements of eculizumab blood concentration and free C5 from multiple complement-mediated diseases, including PNH. Using statistical modeling, the authors estimated a concentration range around which complete C5 inhibition becomes more likely, and reported that adding synthetic data narrowed the uncertainty around that estimate. Because this approach used digitized public data and did not test outcomes like symptoms or thrombosis, it mainly informs research on how drug levels relate to a lab marker of C5 activity. [7]

One report focused on complement activation testing and standardization in Japan and stated that the Ba marker predicted thrombotic microangiopathy after stem cell transplantation, and that complement activation was more frequent postpartum than during pregnancy. These statements point to growing interest in using complement markers to track risk in specific situations, but the summary did not provide details like sample size or how widely the testing approach is used in routine care. In a separate policy editorial, authors argued that at least half of people with PNH worldwide lack access to complement inhibitors, and described a collaboration intended to expand availability in many countries. [8] [9]

For patients, these papers mostly matter as signals of what may shape future care rather than something that changes decisions now. The lab-engineered C5 fusion protein and the eculizumab concentration modeling are early-stage efforts to understand and potentially improve how completely the complement system can be blocked, but they do not tell us whether people would feel better or have fewer complications. The complement-marker report suggests that blood markers like Ba may help identify higher-risk periods or transplant-related complications in research settings, but key practical details were not provided in the summary. The access editorial matters now in a different way: it highlights that where someone lives can strongly affect whether they can receive complement inhibitors at all, which can shape outcomes regardless of scientific progress. [6] [7] [8] [9]

This month included a single case that connects PNH-type cells with aplastic anemia in a specific cancer-treatment context. The report described aplastic anemia developing during durvalumab maintenance therapy for lung cancer, along with detection of PNH-type blood cells. The patient improved after immunosuppressive treatment, but a single case cannot show how often this happens or predict risk for others. [10]

In this 76-year-old woman, testing showed a very low-cell bone marrow and PNH-type cells on diagnostic workup. After starting anti-thymocyte globulin, cyclosporine A, and eltrombopag, the report states she had a favorable blood count response. For readers, the main point is that PNH-type cells can sometimes appear alongside aplastic anemia, including in complex medical situations, and management may involve treatments aimed at the bone marrow rather than complement alone. [10]

For patients and caregivers, this case mainly adds awareness that PNH-type cells can be found when aplastic anemia occurs, and that the clinical focus in such situations may be on bone marrow failure. It may matter later if more reports clarify how immune-based cancer therapies relate to aplastic anemia and PNH-type findings, but one case cannot establish a general pattern. What remains uncertain is how commonly this combination occurs and how closely the course would match someone else with different health conditions or treatments. [10]